Mind Medicine (MindMed) Inc. 8-K

What Happened

• Mind Medicine (MindMed) filed an 8-K on January 12, 2026 reporting two main developments: it is rebranding to Definium Therapeutics, Inc., and it posted a corporate presentation that discloses an unaudited, preliminary estimate of cash, cash equivalents and investments of approximately $412 million as of December 31, 2025. The Board approved the name change and the company filed a Notice of Alteration with the British Columbia Registrar on January 9, 2026. The filing was signed by CEO Robert Barrow.

Key Details

• Name change: Mind Medicine (MindMed) Inc. → Definium Therapeutics, Inc.; approved Jan 9, 2026.
• Ticker: Common Shares will trade on Nasdaq under the new symbol "DFTX" effective market open Jan 13, 2026; CUSIP remains unchanged.
• Preliminary cash position: approximately $412 million in cash, cash equivalents and investments as of Dec 31, 2025 (unaudited and subject to completion).
• Independent auditor note: KPMG LLP has not audited, reviewed, or compiled the preliminary cash estimate and expresses no assurance on it. Corporate presentation and press release posted Jan 12, 2026.

Why It Matters

• The rebrand and ticker change reflect a strategic repositioning; no shareholder action is required.
• The preliminary $412M cash estimate gives investors an early view of the company’s liquidity and potential runway, but it is unaudited and may change when finalized.
• Trading under a new ticker (DFTX) may affect how investors find and track the stock; keep an eye on the finalized financials and any audited disclosures for confirmed cash and operational metrics.